A bipartisan group of federal lawmakers is pushing to remove long-standing regulatory barriers that have limited the use of psychedelics in research and compassionate care. Senators Cory Booker (D-N.J.) and Rand Paul (R-KY) recently introduced an updated version of the Breakthrough Therapies Act in the Senate. If passed, the legislation would make it easier to use Schedule I drugs with a breakthrough therapy designation, such as those used in MDMA therapy, enabling more clinical investigation and patient access to potentially transformative treatments.
The legislation specifically targets substances like MDMA and psilocybin, which currently remain classified as Schedule I drugs under federal law. Under the proposed changes, drugs with a breakthrough therapy designation could be reclassified as Schedule II. This shift would reduce the bureaucratic hurdles that have historically slowed research and limited compassionate use, making it simpler for patients to access promising therapies while allowing scientists to expand clinical studies.
According to recent studies, certain Schedule I substances such as MDMA and psilocybin could offer major advancements in the treatment of depression, severe post-traumatic stress disorder, and addiction. This bill aims to eliminate unreasonably burdensome rules and regulations that delay or prevent researchers from studying these breakthrough mental health treatments, and will provide access to these promising therapies for eligible patients who urgently need care.
A companion version of the legislation is set to be introduced in the House by Representatives Nancy Mace (R-SC) and Madeleine Dean (D-PA), demonstrating strong bipartisan interest in reforming federal restrictions around psychedelic-assisted therapy.
Psychedelics in Research: Growing Evidence of Effectiveness
Research into psychedelics has accelerated in recent years, with studies showing meaningful results in mental health care. A notable example is the August study published in JAMA, which examined patients with alcohol use disorder (AUD) who underwent psilocybin-assisted therapy. Participants in the study experienced a significant reduction in heavy drinking days, suggesting that psychedelic-assisted treatment could be a valuable tool in addressing addiction.
Meanwhile, the Multidisciplinary Association for Psychedelic Studies (MAPS) has led landmark research on MDMA therapy for post-traumatic stress disorder (PTSD). MAPS completed its second Phase 3 trial supporting MDMA therapy’s FDA approval in 2022 and anticipates an FDA evaluation by the end of the year. Their first Phase 3 trial showed that 88% of participants with severe PTSD who received MDMA therapy saw significant symptom reduction, compared to 60% in the placebo group.
These findings reinforce the growing consensus that MDMA therapy and other psychedelic-assisted treatments can play a critical role in treating treatment-resistant mental illnesses, offering hope for patients who have not responded to traditional therapies. By lowering regulatory barriers, the Breakthrough Therapies Act could accelerate access to MDMA therapy while fostering additional research.
Addressing the Need for Compassionate Use
Beyond research, the bill also addresses compassionate use cases, where patients with severe or treatment-resistant conditions could benefit from MDMA therapy before full FDA approval. For many patients, especially veterans or individuals with chronic PTSD, waiting years for regulatory processes can mean the difference between recovery and ongoing suffering. By facilitating earlier access under regulated circumstances, the legislation aims to balance patient safety with timely access to potentially lifesaving treatments.
Breakthrough therapies give the opportunity to improve the lives of all those suffering from treatment-resistant mental illnesses. Lawmakers emphasize the duty to ensure veterans and other patients have access to every possible treatment option that shows promise, including MDMA therapy and psilocybin-assisted therapies. This legislation is intended to remove the bureaucratic hurdles that have hindered critical research and compassionate use of potentially lifesaving therapies.
The Broader Impact of the Breakthrough Therapies Act
If enacted, the Breakthrough Therapies Act could reshape the landscape of mental health treatment in the U.S. By reclassifying breakthrough-designated psychedelics from Schedule I to Schedule II, the bill would make it easier for researchers to conduct large-scale clinical trials and for eligible patients to receive treatments under medical supervision. This includes expanded access to MDMA therapy, which continues to show high success rates in treating PTSD and other serious conditions.
Advocates of the bill emphasize that this legislation does not eliminate oversight; rather, it streamlines the path for scientifically validated, potentially lifesaving treatments while maintaining appropriate safety standards. For patients, clinicians, and researchers alike, the bill represents a meaningful step toward expanding treatment options in an area of medicine that has seen slow progress for decades.
As studies continue to show promising outcomes for psychedelic-assisted therapies, including MDMA therapy, removing unnecessary regulatory barriers could accelerate both scientific discovery and patient recovery. For those struggling with treatment-resistant mental illnesses, the Breakthrough Therapies Act may offer not just hope—but a tangible pathway to access therapies that could transform lives.
